JDD Article Highlight
Could targeting the JAK/STAT pathway redefine how we approach cutaneous lupus erythematosus (CLE)? Spanning acute (ACLE), subacute (SCLE), and chronic (CCLE) forms, CLE presents a spectrum of challenges, from varying lesion duration to distinct degrees of skin involvement. While traditional therapies like photoprotection and corticosteroids remain foundational, emerging immunomodulatory treatments, particularly JAK inhibitors, are drawing attention for their potential role in managing these diverse subtypes.
Delve into the evolving landscape of CLE care, exploring diagnosis, treatment strategies, and the promise of novel therapies reshaping outcomes in autoimmune dermatology.
Read more here:
https://jddonline.com/articles/role-of-jak-inhibitors-in-treatment-of-cutaneous-lupus-erythematosus-review-S1545961624P8045X/
